Bo Jesper Hansen, Portfolio Advisor
Bo Jesper, M.D., Ph.D. was the Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB) until 2016. SOBI is a biotech company listed on the Swedish stock exchange and at the time had a market capitalization of around 3,5 billion euros. He is Chairman of Karolinska Development AB and is also non-executive Director of the biotech company Orphazyme ApS. Bo Jesper served as CEO and President to the Board of Swedish Orphan International (1998-2010) until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He then became the company’s executive chairman. He also was non-executive Director of Gambro until its acquisition by Baxter, as well as of Zymenex, until its acquisition by Chiesi. Bo Jesper was the Executive Chairman of Ablynx until its acquisition by Sanofi, as well as of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for the multinationals Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. He has also been a board member with the companies TopoTarget A/S, CMC AB, MipSalus Aps, Kontrast AB, Hyperion Therapeutics, Inc. Newron Pharmaceuticals S.p.A, Novagali Pharma S.A. and VivolutionA/S.
Bo Jesper has an extensive knowledge within clinical study design, regulatory, pharmacovigilance, and business development. He has an M.D. in Urology and a PhD from the University of Copenhagen. Patrick and Bo Jesper first met in 2012 as members of the supervisory board of biotech company Orphazyme S.p.A.